secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001104659-23-040537
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio reports Q4 2022 net loss of $7.7M; advances buntanetap trials
-------------------------------------------------------------------------

- Net loss Q4 2022 of $7.7M vs $5.9M in Q4 2021; full-year net loss $25.3M vs $14.5M.
- Cash and equivalents $28.4M as of Dec 31, 2022; R&D spend $6.2M in Q4, up 114% YoY.
- FDA authorized Phase 2/3 Alzheimer's trial; EU sites approved for Phase 3 Parkinson's trial.
- Interim analysis for Phase 3 PD trial based on 132 patients; company proceeds as planned.
- Appointed VP Process Chemistry and VP Toxicology; filed patent for neuropsychiatric uses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/0001104659-23-040537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923040537/tm2311180d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer